Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNN3 | Q9UGI6 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | MAPT | P10636 | 4/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | JAK2 | O60674 | 2/20 | 0.42 |
| ▸ | JAK3 | P52333 | 2/20 | 0.42 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.42 |
| ▸ | MET | P08581 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.40 |
| ▸ | GFER | P55789 | 1/20 | 0.40 |
| ▸ | PDE5A | O76074 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | PDE4A | P27815 | 1/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.39 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18050975 | 0.87 | CDK2 (0.45) | KCNN3POLBALDH1A1L3MBTL1GAA | |
| SCHEMBL18051068 | 0.84 | KCNN3 (0.46) | KCNN3POLBALDH1A1L3MBTL1GAA | |
| SCHEMBL19912781 | 0.81 | KCNN3 (0.62) | KCNN3POLBALDH1A1L3MBTL1GAA | |
| SCHEMBL14194734 | 0.80 | GSK3B (0.57) | ALDH1A1KDM4EGSK3B | |
| SCHEMBL14194717 | 0.78 | CDK2 (0.50) | GSK3B | |
| SCHEMBL19896512 | 0.78 | CDK2 (0.59) | JAK2JAK3PTK2METHRH4 | |
| SCHEMBL14194767 | 0.77 | GSK3B (0.37) | GSK3B | |
| SCHEMBL14194738 | 0.77 | GSK3B (0.41) | GSK3B | |
| SCHEMBL17690303 | 0.77 | CDK2 (0.38) | GSK3BHTT | |
| SCHEMBL14194733 | 0.77 | GHSR (0.39) | GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11186576-B2 | Pyrazolo[1,5-A][1,3,5]triazine and pyrazolo[1,5-A]pyrimidine derivatives as CDK inhibitors | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2021-11-30 | — | — | US | disclosed |
| US-11186576-B2 | Pyrazolo[1,5-A][1,3,5]triazine and pyrazolo[1,5-A]pyrimidine derivatives as CDK inhibitors | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2021-11-30 | — | — | US | disclosed |
| EP-3268000-B1 | PYRAZOLO[1,5-A][1,3,5]TRIAZINE AND PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES AS CDK INHIBITORS | AURIGENE DISCOVERY TECH LTD (IN) | 2021-08-04 | — | — | EP | disclosed |
| US-20180258092-A9 | Pyrazolo[1,5-A][1,3,5]Triazine and Pyrazolo[1,5-A]Pyrimidine Derivatives as CDK Inhibitors | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2018-09-13 | — | — | US | disclosed |
| US-20180057497-A1 | Pyrazolo[1,5-A][1,3,5]Triazine and Pyrazolo[1,5-A]Pyrimidine Derivatives as CDK Inhibitors | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2018-03-01 | — | — | US | disclosed |
| US-20180057497-A1 | Pyrazolo[1,5-A][1,3,5]Triazine and Pyrazolo[1,5-A]Pyrimidine Derivatives as CDK Inhibitors | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2018-03-01 | — | — | US | disclosed |
| US-20180057497-A1 | Pyrazolo[1,5-A][1,3,5]Triazine and Pyrazolo[1,5-A]Pyrimidine Derivatives as CDK Inhibitors | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2018-03-01 | — | — | US | disclosed |
| EP-3268000-A2 | PYRAZOLO[1,5-A][1,3,5]TRIAZINE AND PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES AS CDK INHIBITORS | Aurigene Discovery Technologies Limited (IN) | 2018-01-17 | — | — | EP | disclosed |
| WO-2016142855-A2 | PYRAZOLO[1,5-A][1,3,5]TRIAZINE AND PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES AS CDK INHIBITORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2016-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180057497-A1 | Pyrazolo[1,5-A][1,3,5]Triazine and Pyrazolo[1,5-A]Pyrimidine Derivatives as CDK Inhibitors | CDK15, CDK1, CDK19 | KCNN3 2255/4885POLB 300/4885ALDH1A1 4435/4885 |
| US-11186576-B2 | Pyrazolo[1,5-A][1,3,5]triazine and pyrazolo[1,5-A]pyrimidine derivatives as CDK inhibitors | CDK15, CDK1, CDK19 | KCNN3 2255/4885POLB 300/4885ALDH1A1 4435/4885 |
| US-20180258092-A9 | Pyrazolo[1,5-A][1,3,5]Triazine and Pyrazolo[1,5-A]Pyrimidine Derivatives as CDK Inhibitors | CDK15, CDK1, CDK19 | KCNN3 2255/4885POLB 300/4885ALDH1A1 4435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.